Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH
Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human clinical trial of the company’s next-generation imipridone ONC206 at the National Institutes of Health (“NIH”). The Phase I trial, for adults with recurrent primary central nervous system (CNS) neoplasms, is led by Mark Gilbert, MD,